TROP2 is highly expressed in triple-negative breast cancer CTCs and is a potential marker for epithelial mesenchymal CTCs
Circulating tumor cells (CTCs) are the seeds of distant metastases of malignant tumors and are associated with malignancy and risk of metastasis. However, tumor cells undergo epithelial-mesenchymal transition (EMT) during metastasis, leading to the emergence of different types of CTCs. Real-time dyn...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-03-01
|
| Series: | Molecular Therapy: Oncology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2950329924000043 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850129514339762176 |
|---|---|
| author | Qingyu Liao Ruiming Zhang Zuli Ou Yan Ye Qian Zeng Yange Wang Anqi Wang Tingmei Chen Chengsen Chai Bianqin Guo |
| author_facet | Qingyu Liao Ruiming Zhang Zuli Ou Yan Ye Qian Zeng Yange Wang Anqi Wang Tingmei Chen Chengsen Chai Bianqin Guo |
| author_sort | Qingyu Liao |
| collection | DOAJ |
| description | Circulating tumor cells (CTCs) are the seeds of distant metastases of malignant tumors and are associated with malignancy and risk of metastasis. However, tumor cells undergo epithelial-mesenchymal transition (EMT) during metastasis, leading to the emergence of different types of CTCs. Real-time dynamic molecular and functional typing of CTCs is necessary to precisely guide personalized treatment. Most CTC detection systems are based on epithelial markers that may fail to detect EMT CTCs. Therefore, it is clinically important to identify new markers of different CTC types. In this study, bioinformatics analysis and experimental assays showed that trophoblast cell surface antigen 2 (TROP2), a target molecule for advanced palliative treatment of triple-negative breast cancer (TNBC), was highly expressed in TNBC tissues and tumor cells. Furthermore, TROP2 can promote the migration and invasion of TNBC cells by upregulating EMT markers. The specificity and potential of TROP2 as an EMT-associated marker of TNBC CTCs were evaluated by flow cytometry, immunofluorescence, spiking experiments, and a well-established CTC assay. The results indicated that TROP2 is a potential novel CTC marker associated with EMT, providing a basis for more efficacious markers that encompass CTC heterogeneity in patients with TNBC. |
| format | Article |
| id | doaj-art-526a37691e4a43f68cfd4d31bd31f899 |
| institution | OA Journals |
| issn | 2950-3299 |
| language | English |
| publishDate | 2024-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Molecular Therapy: Oncology |
| spelling | doaj-art-526a37691e4a43f68cfd4d31bd31f8992025-08-20T02:32:57ZengElsevierMolecular Therapy: Oncology2950-32992024-03-0132120076210.1016/j.omton.2024.200762TROP2 is highly expressed in triple-negative breast cancer CTCs and is a potential marker for epithelial mesenchymal CTCsQingyu Liao0Ruiming Zhang1Zuli Ou2Yan Ye3Qian Zeng4Yange Wang5Anqi Wang6Tingmei Chen7Chengsen Chai8Bianqin Guo9Key Laboratory of Clinical Laboratory Diagnostics (Ministry of Education), College of Laboratory Medicine, Chongqing Medical University, Chongqing 400016, ChinaKey Laboratory of Clinical Laboratory Diagnostics (Ministry of Education), College of Laboratory Medicine, Chongqing Medical University, Chongqing 400016, ChinaKey Laboratory of Clinical Laboratory Diagnostics (Ministry of Education), College of Laboratory Medicine, Chongqing Medical University, Chongqing 400016, ChinaKey Laboratory of Clinical Laboratory Diagnostics (Ministry of Education), College of Laboratory Medicine, Chongqing Medical University, Chongqing 400016, ChinaKey Laboratory of Clinical Laboratory Diagnostics (Ministry of Education), College of Laboratory Medicine, Chongqing Medical University, Chongqing 400016, ChinaKey Laboratory of Clinical Laboratory Diagnostics (Ministry of Education), College of Laboratory Medicine, Chongqing Medical University, Chongqing 400016, ChinaCAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Key Laboratory of Standardization and Measurement for Nanotechnology, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing100190, ChinaKey Laboratory of Clinical Laboratory Diagnostics (Ministry of Education), College of Laboratory Medicine, Chongqing Medical University, Chongqing 400016, ChinaKey Laboratory of Clinical Laboratory Diagnostics (Ministry of Education), College of Laboratory Medicine, Chongqing Medical University, Chongqing 400016, China; Corresponding author: Chengsen Chai, Key Laboratory of Clinical Laboratory Diagnostics (Ministry of Education), College of Laboratory Medicine, Chongqing Medical University, Chongqing 400016, China.Key Laboratory of Clinical Laboratory Diagnostics (Ministry of Education), College of Laboratory Medicine, Chongqing Medical University, Chongqing 400016, China; Department of Clinical Laboratory, Chongqing University Cancer Hospital, Chongqing 40030, China; Corresponding author: Bianqin Guo, Key Laboratory of Clinical Laboratory Diagnostics (Ministry of Education), College of Laboratory Medicine, Chongqing Medical University, Chongqing 400016, China.Circulating tumor cells (CTCs) are the seeds of distant metastases of malignant tumors and are associated with malignancy and risk of metastasis. However, tumor cells undergo epithelial-mesenchymal transition (EMT) during metastasis, leading to the emergence of different types of CTCs. Real-time dynamic molecular and functional typing of CTCs is necessary to precisely guide personalized treatment. Most CTC detection systems are based on epithelial markers that may fail to detect EMT CTCs. Therefore, it is clinically important to identify new markers of different CTC types. In this study, bioinformatics analysis and experimental assays showed that trophoblast cell surface antigen 2 (TROP2), a target molecule for advanced palliative treatment of triple-negative breast cancer (TNBC), was highly expressed in TNBC tissues and tumor cells. Furthermore, TROP2 can promote the migration and invasion of TNBC cells by upregulating EMT markers. The specificity and potential of TROP2 as an EMT-associated marker of TNBC CTCs were evaluated by flow cytometry, immunofluorescence, spiking experiments, and a well-established CTC assay. The results indicated that TROP2 is a potential novel CTC marker associated with EMT, providing a basis for more efficacious markers that encompass CTC heterogeneity in patients with TNBC.http://www.sciencedirect.com/science/article/pii/S2950329924000043MT: Regular Issuecirculating tumor cellsCTCstriple-negative breast cancerTNBCtrophoblast cell surface antigen 2 |
| spellingShingle | Qingyu Liao Ruiming Zhang Zuli Ou Yan Ye Qian Zeng Yange Wang Anqi Wang Tingmei Chen Chengsen Chai Bianqin Guo TROP2 is highly expressed in triple-negative breast cancer CTCs and is a potential marker for epithelial mesenchymal CTCs Molecular Therapy: Oncology MT: Regular Issue circulating tumor cells CTCs triple-negative breast cancer TNBC trophoblast cell surface antigen 2 |
| title | TROP2 is highly expressed in triple-negative breast cancer CTCs and is a potential marker for epithelial mesenchymal CTCs |
| title_full | TROP2 is highly expressed in triple-negative breast cancer CTCs and is a potential marker for epithelial mesenchymal CTCs |
| title_fullStr | TROP2 is highly expressed in triple-negative breast cancer CTCs and is a potential marker for epithelial mesenchymal CTCs |
| title_full_unstemmed | TROP2 is highly expressed in triple-negative breast cancer CTCs and is a potential marker for epithelial mesenchymal CTCs |
| title_short | TROP2 is highly expressed in triple-negative breast cancer CTCs and is a potential marker for epithelial mesenchymal CTCs |
| title_sort | trop2 is highly expressed in triple negative breast cancer ctcs and is a potential marker for epithelial mesenchymal ctcs |
| topic | MT: Regular Issue circulating tumor cells CTCs triple-negative breast cancer TNBC trophoblast cell surface antigen 2 |
| url | http://www.sciencedirect.com/science/article/pii/S2950329924000043 |
| work_keys_str_mv | AT qingyuliao trop2ishighlyexpressedintriplenegativebreastcancerctcsandisapotentialmarkerforepithelialmesenchymalctcs AT ruimingzhang trop2ishighlyexpressedintriplenegativebreastcancerctcsandisapotentialmarkerforepithelialmesenchymalctcs AT zuliou trop2ishighlyexpressedintriplenegativebreastcancerctcsandisapotentialmarkerforepithelialmesenchymalctcs AT yanye trop2ishighlyexpressedintriplenegativebreastcancerctcsandisapotentialmarkerforepithelialmesenchymalctcs AT qianzeng trop2ishighlyexpressedintriplenegativebreastcancerctcsandisapotentialmarkerforepithelialmesenchymalctcs AT yangewang trop2ishighlyexpressedintriplenegativebreastcancerctcsandisapotentialmarkerforepithelialmesenchymalctcs AT anqiwang trop2ishighlyexpressedintriplenegativebreastcancerctcsandisapotentialmarkerforepithelialmesenchymalctcs AT tingmeichen trop2ishighlyexpressedintriplenegativebreastcancerctcsandisapotentialmarkerforepithelialmesenchymalctcs AT chengsenchai trop2ishighlyexpressedintriplenegativebreastcancerctcsandisapotentialmarkerforepithelialmesenchymalctcs AT bianqinguo trop2ishighlyexpressedintriplenegativebreastcancerctcsandisapotentialmarkerforepithelialmesenchymalctcs |